Nippon Shinyaku recently reported progress on two Phase 2 trials of its oral candidate NS-863, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), both serious cardiopulmonary conditions with high unmet need.
By advancing NS-863 across two related indications, the company is signaling a deeper push into rare cardiopulmonary therapeutics, potentially broadening its specialty portfolio.
Read more here from Simply Wall ST and at this link on the Nippon Shinyaku